Search

Displaying results 2581 - 2590 of 10000 in total
  1. Drug

    Calfactant

    go.drugbank.com/drugs/DB06415
    ApprovedInvestigational

    It adsorbs to the air:fluid interface in the lungs and works to reduce surface tension, in a manner similar to endogenous pulmonary surfactant. … Calfactant has been shown to decrease the incidence of respiratory distress syndrome, mortality due to respiratory distress syndrome, and air leaks associated with respiratory distress syndrome in clinical

  2. Drug

    Etravirine

    go.drugbank.com/drugs/DB06414
    ApprovedInvestigational

    On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral … Common side effects of use include mild to moderate rash within the first 6 weeks of therapy, nausea, diarrhea and peripheral neuropathy.

  3. Drug

    Nuvaxovid

    go.drugbank.com/drugs/DB15810
    ApprovedInvestigational

    [L49111] In the fall of 2024, an updated formulation covering the Omicron JN.1 subvariant was approved for use in Canada and the US.[L51394,L51399] … SARS-CoV-2, the causative agent of COVID-19, relies on the interaction between its trimeric spike (S) glycoprotein and angiotensin-converting enzyme 2 (hACE2) expressed on host cells in order to establish

  4. Drug

    Cefiderocol

    go.drugbank.com/drugs/DB14879
    ApprovedInvestigational

    54.6% with the comparator, imipenem/cilastatin. … [A189057] It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase

  5. Drug

    Chloroxine

    go.drugbank.com/drugs/DB01243
    ApprovedWithdrawn

    Chloroxine is a compound used in some shampoos for the treatment of dandruff and seborrheic dermatitis of the scalp.

  6. Drug

    Valoctocogene roxaparvovec

    go.drugbank.com/drugs/DB15561
    ApprovedInvestigationalWithdrawn

    [L43282] The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active factor VIII in blood. … [A252797] As opposed to these therapies, valoctocogene roxaparvovec offers the advantage of continuous and measurable steady-state levels of coagulation factor VIII.[A252807]

  7. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    [L48676] Vamorolone is positioned as having a more tolerable adverse effect profile than other corticosteroids owing to its unique receptor binding profile,[A261976] thus providing an additional treatment … and the most common form of muscular dystrophy in the United States.

  8. Drug

    Latamoxef

    go.drugbank.com/drugs/DB04570
    Approved

    Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins … It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.

  9. Drug

    Etoperidone

    go.drugbank.com/drugs/DB09194
    ApprovedWithdrawn

    Etoperidone is an atypical antidepressant introduced in Europe in 1977. It is a phenylpiperazine-substituted triazole derivative with a composition that classifies it as an analog of tradozone and presents a similar pharmacological profi...

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor Antagonists
  10. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L52043] By inhibiting TFPI, concizumab enhances the production of factor Xa via the extrinsic clotting pathway. … [L52043] One disadvantage of this approach is the possible development of antibodies (inhibitors) towards the administered replacement factor, rendering them less effective and increasing the likelihood